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Only ~50% of patients with diffuse large B-cell lymphoma (DLBCL), the most common and 
aggressive subtype of non-Hodgkin’s lymphoma, enter long-term remission after standard 
chemotherapy, and patients who do not respond to treatment have few options. Therefore, there 
is a critical need for effective and targeted therapeutics for DLBCL. Recent studies highlight the 
incidence of increased c-MYC protein in DLBCL and the correlation between high levels of c-
MYC and poor survival prognosis of DLBCL patients, suggesting that c-MYC is a compelling 
therapeutic target for DLBCL therapy. The small molecule JQ1 suppresses c-MYC expression 
through inhibition of the BET family of bromodomain proteins. We show that JQ1 efficiently 
inhibited cell proliferation of human DLBCL cells regardless of their molecular subtypes, 
suggesting a broad effect of JQ1 in DLBCL. After JQ1 treatment, initial G1 arrest in DLBCL cells 
was followed by either apoptosis or senescence. In DLBCL cells treated with JQ1, we found that 
c-MYC expression was suppressed in the context of the natural, chromosomally-translocated or 
an amplified gene locus. Furthermore, JQ1 treatment significantly suppressed growth of DLBCL 
cells engrafted subcutaneously and improved survival of mice engrafted with DLBCL cells 
intraperitoneally. These results demonstrate that inhibition of the BET family of bromodomain 
proteins, and consequently c-MYC, has the potential clinical utility in DLBCL treatment.  
 
